Jakob Dynnes Hansen
Jakob Dynnes Hansen has more than 25 years of combined experience from biotech and financing. He has been CFO in several biotech companies, including Acesion Pharma, Evolva, Nuevolution, and Zealand Pharma. As CFO, he has played a key role in two IPO’s, two cross-border acquisitions, a multitude of financing rounds and several licensing deals. Before moving into biotech, Jakob was a senior member of the Corporate Finance Team at Unibank (now Nordea) and he has been Head of Market Research at Novo Nordisk. He also holds the position as CFO of Asarina Pharma. Jakob has an MSc in Economics from the University of Copenhagen and an MBA from INSEAD.